FC
CRNX icon

Finepoint Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Finepoint Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-797,527
Closed -$14.4M – 32
2023
Q2 		$14.4M Sell
797,527
-70,900
-8% -$1.41M 4.97% 11
2023
Q1 		$13.9M Buy
868,427
+45,682
+6% +$845K 5.33% 13
2022
Q4 		$15.1M Buy
+822,745
New +$14.5M 4.87% 14

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Finepoint Capital's CRNX Position: Q3 2023 in Review

Finepoint Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 797,527 shares — an estimated $14.4M sold.

Finepoint Capital first reported a position in CRNX in Q4 2022 and held it in 3 quarters. The position peaked at $15.1M in Q4 2022. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

  • Finepoint Capital reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Finepoint Capital sold 797,527 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $14.4M.
  • Finepoint Capital first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Finepoint Capital's Crinetics Pharmaceuticals position peaked at $15.1M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on Finepoint Capital's 13F filing for Q3 2023, filed 13 Nov 2023.